Camber Capital Management’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Camber Capital Management’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,847,500	Closed	-$835K	–	50
2016 Q2	$835K	Hold	1,847,500	–	–	0.04%	47
2016 Q1	$4.97M	Hold	1,847,500	–	–	0.29%	42
2015 Q4	$5.71M	Hold	1,847,500	–	–	0.37%	37
2015 Q3	$8.17M	Hold	1,847,500	–	–	0.7%	32
2015 Q2	$10.5M	Hold	1,847,500	–	–	0.72%	34
2015 Q1	$16.5M	Buy	+1,847,500	New	+$14.8M	1.18%	25

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Camber Capital Management's EPRS Position: Q3 2016 in Review

Camber Capital Management sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 1,847,500 shares — an estimated $835K sold.

Camber Capital Management first reported a position in EPRS in Q1 2015 and held it in 6 quarters. The position peaked at $16.5M in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

Camber Capital Management reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
Camber Capital Management sold 1,847,500 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016, an estimated $835K.
Camber Capital Management first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 6 quarters.
Camber Capital Management's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $16.5M in Q1 2015.
3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Camber Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.